Elevance Health, Inc.
$394.48+$4.32 (+1.1%)
Last close · Data as of Nov 20, 2026
- Market cap
- $88.9B
- P/E
- 15.7x
- Revenue
- $199.1B
- Net margin
- 2.8%
- ROCE
- 10.7%
Price chart
Technical chartScreen technicals →+25.6% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -10.4%
- 3M
- -0.5%
- 6M
- -0.4%
- 1Y
- +25.6%
- 5Y
- -5.0%
52-week range
Day change +$4.32 (+1.1%) from $390 to $394 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in ELV, bought on each weekday since 2021.
News & filings
What Elevance Health filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernOther income of 24.5 billion US dollars was 12% of revenue in fiscal 2025.
Strengths (1)
- Operating profit was 5.8 times interest costs.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other.
Read moreShow less
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.
- Sector
- Healthcare
- Shares outstanding
- 220.7M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $88.9B
- P/E
- 15.7x
- P/B
- 2.0x
- EV / Sales
- 0.6x
- P/S
- 0.4x
- 52-week high
- $446.28
- 52-week low
- $280.74
Profitability
- Operating margin
- 4.1%
- Net margin
- 2.8%
- ROE
- 12.9%
- ROCE
- 10.7%
- ROA
- 4.7%
- Asset turnover
- 1.64
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $199.1B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 12.6%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 8.3%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -5.3%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $3.2B
Solvency
- Debt / Equity
- 0.73
- Debt / Assets
- 0.26
- CFO / Net profit
- 0.76
- Cash / Market cap
- 10.7%
Where the revenue went
Some FY2025 lines are not reported, so the ones that are appear as a table.
| Line | FY2025 |
|---|---|
| Revenue | $199.1B |
| Gross profit | $199.1B |
| Pretax income | $6.7B |
| Tax and other | $1.0B |
| Net income | $5.7B |
Revenue and net profit
Revenue grew 12.6% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $156.6B | $5.9B |
| FY2023 | $171.3B | $6.0B |
| FY2024 | $176.8B | $6.0B |
| FY2025 | $199.1B | $5.7B |
Cash flows
FY2025: $4.3B from operations, $3.2B free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $8.4B | $7.2B |
| FY2023 | $8.1B | $6.8B |
| FY2024 | $5.8B | $4.6B |
| FY2025 | $4.3B | $3.2B |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $199.1B+12.6%1Y
- Net profit
- $5.7B-5.3%1Y
- Cash from operations
- $4.3B-26.1%1Y
- Free cash flow
- $3.2B-30.3%1Y
- Revenue CAGR, 3Y
- 8.3%
- Net profit CAGR, 3Y
- -1.3%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $199.1B | — | $5.7B | $3.2B | 12.9% | +12.6% | -5.3% |
Monthly returns
Month-by-month returns of ELV across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $121.5B |
| Current assets | — |
| Non-current assets | — |
| Liabilities | $77.5B |
| Current liabilities | — |
| Non-current liabilities | — |
| Equity | $44.0B |
| Paid-in capital | $8.9B |
| Retained earnings | $35.4B |
| Minority interest | $144.0M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; ELV highlighted.
P/E against peers
ELV trades at 15.7x earnings against a peer median of 20.8x (a 25% discount).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Elevance Health, Inc.ELVthis companyP/E ↓ discount | $88.9B | 15.7x | 2.0x | 12.9% | — |
| Stryker CorporationSYK | $115.5B | 35.6x | 5.2x | 14.5% | 20.2x |
| Vertex Pharmaceuticals IncorporatedVRTX | $112.1B | 28.4x | 6.0x | 21.2% | 22.4x |
| Medtronic plcMDT | $105.2B | 22.6x | 2.2x | 9.7% | 14.3x |
| McKesson CorporationMCK | $91.0B | 19.1x | -41.9x | -219.2% | 13.3x |
| HCA Healthcare, Inc.HCA | $80.3B | 11.8x | -13.3x | -112.6% | 8.2x |
| The Cigna GroupCI | $74.2B | 12.5x | 1.8x | 14.3% | 10.2x |
| Boston Scientific CorporationBSX | $72.6B | 25.1x | 3.0x | 12.0% | 16.1x |
| Regeneron Pharmaceuticals, Inc.REGN | $65.9B | 14.6x | 2.1x | 14.4% | 11.3x |
| Peer median | — | 20.8x | 2.1x | 13.1% | 13.8x |
Year-to-date ROI
ELV since 1 January, against earlier years.
Historical volatility
ELV's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $199.1B |
| Operating expenses | |
| Selling, general and administrativeSelling General And Administration | — |
| Other operating expensesOther Operating Expenses | $42.2B |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $628.0M |
| Amortization | $628.0M |
| Total expensesTotal Expenses | $192.4B |
| Interest and other | |
| Pretax incomePretax Income | $6.7B |
| TaxTax Provision | $1.0B |
| Net incomeNet Income | $5.7B |
| Per share | |
| Supplementary | |
| Other lines |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $121.5B |
| Current assets | |
| Non-current assets | |
| LiabilitiesTotal Liabilities Net Minority Interest | $77.5B |
| Current liabilities | |
| Non-current liabilities | |
| EquityTotal Equity Gross Minority Interest | $44.0B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $4.3B |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $4.3B |
| Net income, continuing operationsNet Income From Continuing Operations | $5.7B |
| Depreciation and amortisationDepreciation And Amortization | $1.5B |
| Stock-based compensationStock Based Compensation | $276.0M |
| Deferred taxDeferred Tax | -$279.0M |
| Deferred income taxDeferred Income Tax | -$279.0M |
| Operating gains and lossesOperating Gains Losses | $255.0M |
| Gain loss on investment securitiesGain Loss On Investment Securities | $653.0M |
| Gain loss on sale of businessGain Loss On Sale Of Business | $0.00 |
| Earnings losses from equity investmentsEarnings Losses From Equity Investments | -$398.0M |
| Asset impairmentAsset Impairment Charge | $108.0M |
| Change in working capitalChange In Working Capital | -$3.3B |
| Investing cash flowInvesting Cash Flow | -$1.3B |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$1.3B |
| Capital expenditureCapital Expenditure | -$1.1B |
| Purchase of PP&EPurchase Of PPE | -$1.1B |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$1.1B |
| AcquisitionsPurchase Of Business | — |
| DisposalsSale Of Business | $88.0M |
| Net acquisitions and disposalsNet Business Purchase And Sale | $88.0M |
| Purchase of investmentsPurchase Of Investment | -$15.0B |
| Sale of investmentsSale Of Investment | $15.1B |
| Net investment purchases and salesNet Investment Purchase And Sale | $69.0M |
| Other investing changesNet Other Investing Changes | -$385.0M |
| Financing cash flowFinancing Cash Flow | -$1.7B |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$1.7B |
| Debt issuedIssuance Of Debt | $6.2B |
| Debt repaidRepayment Of Debt | -$3.9B |
| Net debt issuedNet Issuance Payments Of Debt | $2.3B |
| Short-term debt issuedShort Term Debt Issuance | $3.2B |
| Short-term debt repaidShort Term Debt Payments | -$1.7B |
| Net short-term debt issuedNet Short Term Debt Issuance | $1.5B |
| Long-term debt issuedLong Term Debt Issuance | $3.0B |
| Long-term debt repaidLong Term Debt Payments | -$2.1B |
| Net long-term debt issuedNet Long Term Debt Issuance | $844.0M |
| Net common stock issuedNet Common Stock Issuance | -$2.6B |
| Common stock repurchasedCommon Stock Payments | -$2.6B |
| Share buybacksRepurchase Of Capital Stock | -$2.6B |
| Stock options exercisedProceeds From Stock Option Exercised | $79.0M |
| Dividends paidCash Dividends Paid | -$1.5B |
| Common dividends paidCommon Stock Dividend Paid | -$1.5B |
| Other financing chargesNet Other Financing Charges | -$10.0M |
| Change in cashChanges In Cash | $1.2B |
| Effect of exchange ratesEffect Of Exchange Rate Changes | -500.0% |
| Other cash adjustment outside change in cashOther Cash Adjustment Outside Changein Cash | $0.00 |
| Cash at the start of the yearBeginning Cash Position | $8.3B |
| Cash at the end of the yearEnd Cash Position | $9.5B |
| Free cash flowFree Cash Flow | $3.2B |
Learn while you research
Academy chapters picked for Elevance Health, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read